1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
Letters to the Editors
You have free access to this content
Enhancing predictive ability of IL28B-SNPs for SVR in HCV
Article first published online: 15 DEC 2011
DOI: 10.1111/j.1365-2036.2011.04931.x
© 2011 Blackwell Publishing Ltd
Additional Information
How to Cite
Amanzada, A., Schneider, S., Moriconi, F., Mihm, S., van Thiel, D. H. and Ramadori, G. (2012), Enhancing predictive ability of IL28B-SNPs for SVR in HCV. Alimentary Pharmacology & Therapeutics, 35: 317–318. doi: 10.1111/j.1365-2036.2011.04931.x
Publication History
- Issue published online: 15 DEC 2011
- Article first published online: 15 DEC 2011
References
- 1, , , et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162–72.
- 2, , , et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
- 3, , , et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.
- 4, , , et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–4.
- 5, , , et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–9.
- 6, , , , , . Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection. J Med Virol 1999; 58: 227–34.
- 7, , , et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307–14.